Herbert H. Seltzman

Herbert H. Seltzman

Auto-generated profile, based on publicly available information

Herbert H. Seltzman

Research Triangle Institute, P.O. Box 12194, Research Triangle Park, NC 27709, United States

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
PZPingwei Zhao
Pingwei Zhao
HSHaleli Sharir
Haleli Sharir
AKAnkur Kapur
Ankur Kapur
ACAlan Cowan
Alan Cowan
EGEllen B. Geller
Ellen B. Geller
MAMary Abood
Mary Abood
Known agonists of the orphan receptor GPR35 are kynurenic acid, zaprinast, 5-nitro-2-(3-phenylproplyamino) benzoic acid, and lysophosphatidic acids. Their relatively low affinities for GPR35 and prominent off-target effects at other pathways, however, diminish their utility for understanding GPR35 signaling and for identifying potential therapeutic uses of GPR35. In a screen of the Prestwick Library of drugs and drug-like compounds, we have found that pamoic acid is a potent GPR35 agonist. Pamoic acid is considered by the Food and Drug Administration as an inactive compound that enables long-acting formulations of numerous drugs, such as the antihelminthics oxantel pamoate and pyrantel pamoate; the psychoactive compounds hydroxyzine pamoate (Vistaril) and imipramine pamoate (Tofranil-PM); and the peptide hormones triptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar). We have found that pamoic acid induces a Gi/o-linked, GPR35-mediated increase in the phosphorylation of extracellular signal-regulated kinase 1/2, recruitment of β-arrestin2 to GPR35, and internalization of GPR35. In mice, it attenuates visceral pain perception, indicating an antinociceptive effect, possibly through GPR35 receptors. We have also identified in collaboration with the Sanford-Burnham Institute Molecular Libraries Probe Production Center new classes of GPR35 antagonist compounds, including the nanomolar potency antagonist methyl-5-[(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate (CID2745687). Pamoic acid and potent antagonists such as CID2745687 present novel opportunities for expanding the chemical space of GPR35, elucidating GPR35 pharmacology, and stimulating GPR35-associated drug development. Our results indicate that the unexpected biological functions of pamoic acid may yield potential new uses for a common drug constituent.

2 August 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HSHerbert H. Seltzman
Herbert H. Seltzman
CSCraig Shiner
Craig Shiner
EHErin E. Hirt
Erin E. Hirt
AGAnne F. Gilliam
Anne F. Gilliam
BTBrian F. Thomas
Brian F. Thomas
ISIgor Spigelman
Igor Spigelman

1 February 2014 in Life Sciences
Verified
Journal Article
Closed access
ALAnita H. Lewin
Anita H. Lewin
HSHerbert H. Seltzman
Herbert H. Seltzman
FCF. Ivy Carroll
F. Ivy Carroll
SMS. Wayne Mascarella
S. Wayne Mascarella
PRP. Anantha Reddy
P. Anantha Reddy

10 December 2009 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
HSHerbert H. Seltzman
Herbert H. Seltzman

10 July 2017
Verified
Book Chapter
Closed access
HSHerbert H. Seltzman
Herbert H. Seltzman
RMRangan Maitra
Rangan Maitra
KBKatharine Bortoff
Katharine Bortoff
JHJay Henson
Jay Henson
PRPatricia H. Reggio
Patricia H. Reggio
Joseph TamJoseph Tam
Joseph Tam

12 May 2020 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FCF. Ivy Carroll
F. Ivy Carroll
ALAnita H. Lewin
Anita H. Lewin
SMS. Wayne Mascarella
S. Wayne Mascarella
HSHerbert H. Seltzman
Herbert H. Seltzman
PRP. Anantha Reddy
P. Anantha Reddy